Member Info for Balanced66

gggg21 has a sense of humour?

The bonus scheme, from recollection mentioned a cash payment spread out over 3 years and that if the circumstances of the company did not allow a cash payment then something else like shares from my recollection.

The company is awash with money so no need to pay in shares. Anyway if it is a bonus allocation under the scheme then it would say he has been allocated it so or it wouldn't say that HE bought the shares.

It's quite simple in my mind don't know why people overthink or complicate things.

Not read the earlier comments properly so probably just repeating what has been posted already. He didn't need to buy this many shares - that must be near the top 10 biggest Aim purchases ever?

I understand the incentive plan share price has been reached so there was no need for him to buy this many shares. He doesn't need to support the share price anymore if you go by the earlier conspiracy theories regarding his bonus. He obviously believes in the business going forward. Yes there will be ups and downs but none of us can predict the short term price movements. His purchase is a good guide for investors. Directors are not always right in their purchases or sales either but this is a massive buy and his interests are now aligned to a large extent with those of the shareholders.

If Sng come through p3 successfully then I think it will be worth a lot more than its current price. There will still be demand sufficient to justify a bigger valuation imv as treatments may still be needed even after a vaccine. Worldwide vaccination program may take some time to complete if it ever does cover all countries.

My concern is the the usual risks of awaiting p3 results and risks of failure. But each to their own investing style.

Others will have studied Sng in more depth than me. There still remains a risk that p3 may fail? As we know sometimes the most promising drugs at p2 fail at p3 that's why biotech investing is risky.

Hope it works out for you Nolupus. That vaccine news just came out suddenly and no one was expecting the early indications of 90% effectiveness - 50% was factored into the prices of covid stocks to some extent but 90% wow! Early results so 90% can change.

I still have a tiny holding in Sng which I'll keep now and see what happens.

TSI have a rns today where they review the existing investments and mention Weshop and Weshop's intention to list. Let's hope so it would be good to get an exit on that one.

I'm impressed with some of the investors/traders on this board; you people have got some good trading skills there often buying and selling the same share so many times that it has paid for itself and is a free carry through all the trades made.

I'm watching and learning but don't have the skills yet to do the rinse and repeat method. I've probably added around 8% to my overall performance since March through a few successful trades and after deducting the couple or so that have not been so successful. So trading has improved my performance as well.

I'll continue to watch and learn. Being a traditional type investor with a bit of trading on the side will be good I think for me.

Do you guys use any charts and similar resources etc. for your trading?

Hi all

The way I'm reading the rns it says Spa request was made in July and NOW Fda has responded with a type A meeting. So I don't read that as there have been discussions with Fda since Spa request; type A meeting will be first discussion on Spa. I'm not an expert on these things but that is how I read it.

It's a good rns - all parties are still interested and the delay so far seems to have been from Fda side. What if Fda gave conditional approval for use of drug while new p3 trial done how positive would that be for share price? I think it would be really positive.

Looks like we are going to get our p3 trial soon hopefully.

Following FDA any placing will not be seen as a negative imv as it will allow commercialisation. Don't think they will be short of takers for any future placing. Hope they do an open offer for us pi's and I can see people asking for extra allocation if it is offered in any open offer. I will certainly take my full allocation. It won't stay long at any future placing price imv!

From a 2009 guidance note: "Guidance for Industry
Formal Meetings Between the FDA and Sponsors or
Applicants" I think type A meeting just means it is the meeting type for SPA request, last bullet point. Type B, C meetings discuss other issues. Asking for approval to use the drug before P3 complete shows confidence. I did ask a similar question a few months back - something like I thin - can P3 data from old study be used to speed up shorten new P3 trial.

"III. MEETING TYPES2
There are three types of meetings that occur between sponsors or applicants and FDA staff: Type
A, Type B, and Type C. Each meeting type is subject to different procedures, as described
below.
A. Type A Meeting
A Type A meeting is a meeting needed to help an otherwise stalled product development
program proceed. Examples of a Type A meeting include:
• Dispute resolution meetings as described in 21 CFR 10.75, 312.48, and 314.103 and in
the guidance for industry Formal Dispute Resolution: Appeals Above the Division Level3
• Meetings to discuss clinical holds in which a response to hold issues has been submitted,
but the FDA and the sponsor or applicant agree that the development is stalled and a new
path forward should be discussed
• Special protocol assessment meetings that are requested by sponsors or applicants after
receipt of FDA evaluation of protocols under the special protocol assessment procedures
as described in the guidance for industry Special Protocol Assessment"

It's not about cost. Government just think (mistakenly in my view) that they will be quicker or simpler to use.

I think I should have hedged my portfolio with some more recovery plays from the transport sector etc. Still I'm personally down on some profit - could have been worse.

Lucky timing Eva! Going to be some horror stories today.

All covid shares got battered. Not sure to what degree they will recover now?

I was thinking about this earlier today. Demand for testing remains very strong. If there was any weakening of demand in the bigger markets Nova could push for more sales in the ROW. I don't believe there will be any let up in demand following a vaccine and this was the view in the broker note.

Unfortunately and this is sad but developing countries are very likely to be behind in any vaccination programs as they are prioritised for the richer countries. However this will present opportunities for Nova to sell more tests in those countries.

As has been mentioned with long term contracts demand will be assured for the foreseeable future.

Biden looks like will be getting in to new post and more tests will be done. Good that we have that big US distributor that was mentioned a while back and not heard anything more about.

It would be good to know where they are with the other drug programs. It would be a hold just on those other programs if progress was being made.

This was posted on one of the other boards. Maybe some ideas for some people:

https://www.piworld.co.uk/2020/11/06/piworld-interview-an-hour-with-paul-jourdan/

https://www.piworld.co.uk/2020/11/06/piworld-interview-an-hour-with-paul-jourdan/

I like these posts about resistance points, book turning etc. We can all learn from each other to improve our success in the market.

When Novacyt was much lower than its current share price and the company was not releasing any information about sales or contracts the one clue we had was the massive increase in recruitment and then the huge contract for circa £0.5 billion landed from the government.

I'm seeing the same thing here now - lots of recruitment which is a sure sign that business is booming.

Kaeren

I think the share price speaks for itself and day by day the flaws in his arguments are becoming apparent. New technology will help but it will need to be up to high standards. Good that he is over there and not here.

These people are mostly just timewasters. Today we saw the article by Michael Taylor from the Investors Chronicle. He also writes for Stocko. MT is an expert in charts and trading and trains people etc. Yet he got caught out and left behind. Having read MT's other articles he does not generally research very much or anything of the fundamentals of a company - mostly just relies on the chart which is probably why he missed out on this share. We have had "super" traders and the like here trying to convince people that they have done much better than MT trading the share. That may be true to some extent as it seems MT never revisited the share but it shows you how traders have been caught out yet they come on this board with tales of buying regularly on the lows and selling on the highs and claiming to beat the long term holders. They mostly appear to try to work a low buy in price imv having been left behind.

Not looking good for CS - he'll probably be saying that his company has an Nda and it's all going to happen before Christmas! Hard to believe that think some people are in dreamland.